MYC and leukemia: Co-targeting of AKT and c-MYC has been recently shown to be a synergistic treatment strategy for leukemia therapy [61, 62], since shikonin and its derivatives strongly deregulate the AKT signaling pathway and directly inhibit c-MYC activity.